Grace Therapeutics, Inc. Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations
Grace Therapeutics, Inc. (GRCE) had Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations of $19.39 million as of 2024-06-30, per its 10-Q filed 2024-08-09.
Discontinued › Cash Flow
us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations · last filed 2024-08-09
- 2024-06-30: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations $19.39M.
- 2024-03-31: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations $23.00M.
- 2023-09-30: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations $18.55M; Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations as first filed $26.99M.
- 2023-06-30: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations $21.63M.
| Period end | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations as first filed |
|---|---|---|
| 2024-06-30 | $19.39M 10-Q · filed 2024-08-09 | |
| 2024-03-31 | $23.00M 10-Q · filed 2024-08-09 | |
| 2023-09-30 | $18.55M 10-Q · filed 2024-02-12 | $26.99M 10-Q · filed 2023-11-13 |
| 2023-06-30 | $21.63M 10-Q · filed 2024-08-09 | |
| 2023-03-31 | $27.88M 10-Q · filed 2024-08-09 | |
| 2022-12-31 | $26.24M 10-Q · filed 2023-02-14 | |
| 2022-09-30 | $26.24M 10-Q · filed 2024-02-12 | $34.93M 10-Q · filed 2022-11-14 |
| 2022-06-30 | $38.38M 10-Q · filed 2023-08-11 | |
| 2022-03-31 | $30.34M 10-K · filed 2024-06-21 | |
| 2021-12-31 | $33.01M 10-Q · filed 2023-02-14 | |
| 2021-09-30 | $36.93M 10-Q · filed 2022-11-14 | |
| 2021-06-30 | $40.98M 10-Q · filed 2022-08-11 | |
| 2021-03-31 | $50.94M 10-K · filed 2023-06-23 | |
| 2020-12-31 | $26.55M 10-Q · filed 2022-02-14 | |
| 2020-09-30 | $11.55M 10-Q · filed 2022-02-14 | |
| 2020-06-30 | $12.12M 10-Q · filed 2021-11-10 | |
| 2020-03-31 | $14.24M 10-K · filed 2022-06-21 | |
| 2019-12-31 | $19.77M 10-Q · filed 2021-02-09 | |
| 2019-09-30 | $19.50M 10-Q · filed 2021-02-09 | |
| 2019-06-30 | $15.98M 10-Q · filed 2020-11-16 | |
| 2019-03-31 | $16.87M 10-K · filed 2021-06-22 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| PDS Biotechnology Corp (PDSB) | United States | $0.045B | |
| SCYNEXIS INC (SCYX) | United States | $0.045B | |
| Werewolf Therapeutics, Inc. (HOWL) | United States | $0.047B | |
| VERU INC. (VERU) | United States | $0.043B | -3.93 |
| Dogwood Therapeutics, Inc. (DWTX) | United States | $0.049B | |
| Lite Strategy, Inc. (LITS) | United States | $0.049B | |
| Elicio Therapeutics, Inc. (ELTX) | United States | $0.049B | |
| Kairos Pharma, LTD. (KAPA) | United States | $0.041B | |
| Incannex Healthcare Inc. (IXHL) | $0.040B | -22.32 | |
| Karyopharm Therapeutics Inc. (KPTI) | United States | $0.039B | -0.98 |